Brief: NeuroMetrix Receives FDA Breakthrough Device Designation For Treatment Of Fibromyalgia
20/07/2021 14:16
July 20 (Reuters) - NeuroMetrix Inc NURO.O :
* NEUROMETRIX RECEIVES FDA BREAKTHROUGH DEVICE DESIGNATION
FOR
TREATMENT OF FIBROMYALGIA WITH ITS WEARABLE NEUROSTIMULATION
TECHNOLOGY
Source text for Eikon: ID:nGNX6tRsSD
Further company coverage: NURO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuroMetrix
See all newsBrief: Neurometrix To Be Acquired By Electrocore
Brief: Neurometrix Reiterates Its Review Of Strategic Alternatives
Brief: NeuroMetrix Announces Steps Taken To Enhance Shareholder Value
Brief: Ephraim Fields Reports 9.3% Stake In Neurometrix, Inc. As Of Feb 23, 2024 - SEC Filing
Brief: RS Fund Reports 14.4% Stake In Neurometrix Inc As Of Feb 13